Abstract Details

Title Cortical Surface Area and Subcortical Volume Imaging Differences Between African Americans and Caucasians with Relapsing Remitting Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) S45 - Multiple Sclerosis: Imaging (3:54 PM-4:06 PM)

Poster/Presentation
Number 003

Objective To assess cortical surface area (CSA) and subcortical volume (SCV) between African Americans (AA) and Caucasians (CA) with Relapsing Remitting Multiple Sclerosis (RRMS).

Background It has been shown that there is a faster progression of brain volume loss associated with RRMS. There is also some evidence that AA patients with RRMS experience greater disease disability and disease progression than CA with RRMS. The purpose of this study is to assess SCV and CSA between AA and CA patients with RRMS.

Design/Methods 62 total RRMS patients were included in this retrospective, single center analysis and split into two groups, 32 AA and 30 CA. All MRI images were obtained on a 3.0 Tesla magnet (Siemens Verio System). MRI image processing and analysis was performed using Jim (v6). CSA measures include the following: Fronal (FA), Parietal (PA), Temporal (TA), Occipital (OA), Cingulate (CA), and Global (GA). SCV measures include the following: Thalamus (TV), Caudate (CV), Putamen (PV), Pallidum (PaV), Hippocampus (HV), Amygdala (AV), Accumbens (AcV), Brain Stem (BSV), and Total Volume (TV). A general linear model with multivariate analysis (MANOVA) was used to analyze our data (SPSS vs 25). Treatment, age and disease duration were included as covariates for our analysis.

Results Our results revealed significantly more FA, TA, and GA atrophy in AA versus CA (p=0.007, p=0.021, and p=0.029, respectively). HV was also found to be significantly lower in AA versus CA (p=0.016).

Conclusions Our data suggests AA patients with RRMS experience more CSA and SCV loss than CA RRMS patients. Greater CSA and SCV loss may help explain the more aggressive disease course that AA RRMS patients experience over CA patients with RRMS. Further longitudinal studies with larger samples should be conducted to confirm our findings.

Authors/Disclosures
Melody Gilroy, BS PRESENTER	Ms. Gilroy has nothing to disclose.
Fen Bao	Fen Bao has nothing to disclose.
Carla E. Santiago-Martinez (Wayne State University)	Ms. Santiago-Martinez has nothing to disclose.
Evanthia Bernitsas, MD, FAAN (Wayne State School of Medicine)	Dr. Bernitsas has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen@Janssen. Dr. Bernitsas has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Bernitsas has received research support from Roche/Genentech.

��ɫ��

��ɫ��